Abstract
Ustekinumab therapy changes the transcriptional activity pattern of TGF-β1–3 genes
- Katowice School of Technology, University of Science and Art, Katowice, Poland
- Center of Oncology, M. Sklodowska-Curie Memorial Institute, Cracow Branch, Poland
- Department of Molecular Biology, School of Pharmacy with Division of Laboratory Medicine in Sosnowiec, Medical University of Silesia in Katowice, Poland
- Department of Cosmetology, School of Pharmacy with Division of Laboratory Medicine in Sosnowiec, Medical University of Silesia in Katowice, Poland
- Faculty of Health Science, Public Higher Medical Professional School, Opole, Poland
Introduction
One of the examples of genes whose expression can be altered by the action of ustekinumab is TGF-β. It is a pleiotropic cytokine whose activity affects psoriatic changes and the state of homeostasis of the whole organism.
Aim
To evaluate the effect of ustekinumab on the transcriptional activity of TGF-b family genes in patients with psoriatic arthritis and to check whether the results obtained can be helpful in monitoring the progress of treatment.
Material and methods
From total PBMCs obtained from peripheral blood of 14 patients with psoriatic arthritis, total RNA was isolated. The expression level of the TGF-β1, TGF-β2 and TGF-β3 genes was determined by RT-qPCR in real time.
Results
In all the analysed samples, the presence of mRNA of three TGF-β isoforms was quantitated in each week of therapy. TGF-β3 and the smallest TGF-β2 showed the highest expression. Statistically significant correlations were observed in the amount of TGF-β1 and TGF-β3/µg mRNA RNA, TGF-β2 and TGF-β2/µg RNA and TGF-β3 and TGF-β3/µg RNA.
Conclusions
Ustekinumab influences the transcriptional activity of TGF-β genes, and the changes caused have a bearing on the patient’s health.
Keywords
ustekinumab, TGFβ1-3, psoriasis arthritis, molecular marker
Indexed in
Integrated with
